(NASDAQ: RPID) Rapid Micro Biosystems's forecast annual revenue growth rate of 21.7% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.26%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Rapid Micro Biosystems's revenue in 2026 is $35,176,000.On average, 6 Wall Street analysts forecast RPID's revenue for 2026 to be $2,026,044,786, with the lowest RPID revenue forecast at $1,902,351,321, and the highest RPID revenue forecast at $2,143,568,626. On average, 6 Wall Street analysts forecast RPID's revenue for 2027 to be $2,421,703,364, with the lowest RPID revenue forecast at $2,266,108,421, and the highest RPID revenue forecast at $2,580,709,156.
In 2028, RPID is forecast to generate $3,325,578,563 in revenue, with the lowest revenue forecast at $3,195,163,717 and the highest revenue forecast at $3,423,389,697.